Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
$21.9M Sell
780,224
-129,580
-14% -$3.64M 0.02% 903
2014
Q2
$25.6M Buy
909,804
+594,236
+188% +$16.9M 0.02% 740
2014
Q1
$9.62M Buy
315,568
+107,614
+52% +$3.21M 0.01% 1289
2013
Q4
$6.04M Buy
207,954
+72,831
+54% +$2.12M 0.01% 1694
2013
Q3
$3.68M Sell
135,123
-372,273
-73% -$10.1M ﹤0.01% 1987
2013
Q2
$13.5M Buy
+507,396
New +$14M 0.02% 870

Other funds holding PFE

UBS's PFE Position: Q3 2014 in Review

UBS increased its Pfizer (PFE) stake by 8.4% in Q3 2014, buying an estimated $41.1M and bringing the position to 18,946,615 shares worth $532M. The position accounts for 0.39% of the portfolio, ranked #35.

UBS first reported a position in PFE in Q2 2013 and has held it in 6 quarters since. 1,742 funds tracked by Wall St. Rank hold PFE as of Q3 2014.

  • UBS held 18,946,615 shares of Pfizer worth $532M as of Q3 2014.
  • UBS bought 1,464,015 Pfizer shares in Q3 2014, an estimated $41.1M.
  • Pfizer made up 0.39% of UBS's portfolio in Q3 2014, its #35 holding.
  • UBS first reported a position in Pfizer in Q2 2013 and has held it in 6 quarters since.
  • 1,742 funds tracked by Wall St. Rank held Pfizer as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.